Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
141 participants
OBSERVATIONAL
2021-01-25
2023-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Once enrolled in ReVital-CORE, participants will complete a monthly online evaluation for 1 year. If frailty (or pre-frailty) is detected on any survey, physical or occupational therapy will be initiated for standard of care rehabilitation evaluation and treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rehabilitation Outcomes Study
NCT06674889
Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
NCT07175376
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
NCT05106374
Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer
NCT00769951
Cancer Care Coordination for Chemotherapy Patients
NCT02238951
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants in the ReVital-CORE program study will be emailed an online evaluation each month via for one year. Once completed, the evaluation is automatically scored into: frail, pre-frail or robust categories using a validated frailty index. Any patient categorized as frail or pre-frail will be re-referred to rehabilitation by their cancer care team. For frail and pre-frail individuals, standard of care rehabilitation therapy will include either/and occupational and physical therapy evaluation and treatment and will be billed via their insurance.
The purpose of this pilot study is to evaluate feasibility of the of the ReVital-CORE Program for individuals starting a new chemotherapy regimen. Secondary aims are to evaluate the prevalence, trajectory and predictors of frailty during the first year of chemotherapy treatment; and evaluate the impacts of prehab/rehabilitation for participants identified as frail and pre-frail.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English speaking
* Starting new chemotherapy treatment with oncology partner
* Provide informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Select Medical
UNKNOWN
Kessler Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mackenzi Pergolotti
Senior Director, Research and Clinical Development
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mackenzi Pergolotti, PhD
Role: PRINCIPAL_INVESTIGATOR
Select Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-1132-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.